Azamian Bobak R. sold $906K of TARS (indirect holdings)

Azamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $90.56 ($90.27–$91.27, $0.91M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Azamian Bobak R.
Published Sep 9, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
medium confidence
Mentioned
$TARS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

The transaction is a routine 10b5‑1 sale; market impact is expected to be negligible.

02

Market read

Primary relevance is to Tarsus shareholders; no broader market effect.

03

What to watch

Potential upcoming clinical milestones or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: sale executed on 2026-09-04

Background

Form 4 filings provide the first public disclosure of insider trades.

Company-level read

Ticker impact

$TARSNeutralMedium confidence
Context

President/CEO sold 10,000 shares for $905,600 via a 10b5-1 plan, reducing holdings to 827,991 shares.

Expected impact

Minor downward pressure; likely limited impact on price.

Evidence & confidence

Sale amount is under $1M and follows a pre‑arranged plan, typical for executives; no immediate market reaction expected.

Market effects

No broader sector impact; isolated insider transaction.

None; company is US‑listed biotech with limited regional exposure.

Minimal; only relevant to Tarsus shareholders.

Counterpoint

Insider sale could be interpreted as a lack of confidence, but pre‑arranged plans often mask intent.

Key entities

  • Azamian Bobak R.

    President/CEO and Board Chair of Tarsus Pharmaceuticals.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.